Your browser doesn't support javascript.
loading
Correction: HDAC7 is an actionable driver of therapeutic antibody resistance by macrophages from CLL patients.
Burgess, M; Chen, Y C E; Mapp, S; Blumenthal, A; Mollee, P; Gill, D; Saunders, N A.
Affiliation
  • Burgess M; University of Queensland, Woolloongabba, QLD, Australia.
  • Chen YCE; Department of Haematology, Cancer Services Unit, Princess Alexandra Hospital, Woolloongabba, QLD, Australia.
  • Mapp S; University of Queensland, Woolloongabba, QLD, Australia.
  • Blumenthal A; Department of Haematology, Cancer Services Unit, Princess Alexandra Hospital, Woolloongabba, QLD, Australia.
  • Mollee P; School of Medicine, Translational Research Institute, University of Queensland, Woolloongabba, QLD, Australia.
  • Gill D; University of Queensland Diamantina Institute, Translational Research Institute, Woolloongabba, QLD, Australia.
  • Saunders NA; Department of Haematology, Cancer Services Unit, Princess Alexandra Hospital, Woolloongabba, QLD, Australia.
Oncogene ; 40(6): 1203, 2021 Feb.
Article in En | MEDLINE | ID: mdl-33353962
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Oncogene Journal subject: BIOLOGIA MOLECULAR / NEOPLASIAS Year: 2021 Document type: Article Affiliation country: Australia
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Oncogene Journal subject: BIOLOGIA MOLECULAR / NEOPLASIAS Year: 2021 Document type: Article Affiliation country: Australia